# Yoon‐La Choi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yoon-la-choi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,325 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 73 |
| i10-index | 262 |
| OpenAlex ID | https://openalex.org/A5003089475 |
| ORCID iD | 0000-0002-5788-5140 |
| Works | 497 |

## Researcher papers

- [Genomic Classification of Cutaneous Melanoma](https://scholariq.org/papers/genomic-classification-of-cutaneous-melanoma/)
- [Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma](https://scholariq.org/papers/single-cell-rna-sequencing-demonstrates-the-molecular-and-cellular-reprogramming/)
- [The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma](https://scholariq.org/papers/the-somatic-genomic-landscape-of-chromophobe-renal-cell-carcinoma/)
- [Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial](https://scholariq.org/papers/pembrolizumab-for-patients-with-refractory-or-relapsed-thymic-epithelial-tumor/)
- [Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement](https://scholariq.org/papers/open-label-multicenter-phase-ii-study-of-ceritinib-in-patients-with-non-small/)
- [Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/artificial-intelligence-powered-spatial-analysis-of-tumor-infiltrating/)
- [Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04](https://scholariq.org/papers/multinational-randomized-phase-iii-trial-with-or-without-consolidation/)
- [Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial](https://scholariq.org/papers/vandetanib-in-pretreated-patients-with-advanced-non-small-cell-lung-cancer/)
- [Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases](https://scholariq.org/papers/prognostic-significance-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-a/)
- [Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases](https://scholariq.org/papers/transformation-to-small-cell-lung-cancer-of-pulmonary-adenocarcinoma/)
- [Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer](https://scholariq.org/papers/repeat-biopsy-procedures-and-t790m-rates-after-afatinib-gefitinib-or-erlotinib/)
- [Abstract 4659: AI-powered assessment of morphologic likeness to small cell lung cancer (SCLC) predicts progression to SCLC and TKI response in EGFR-mutant NSCLC](https://scholariq.org/papers/abstract-4659-ai-powered-assessment-of-morphologic-likeness-to-small-cell-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.